Overview of Castrate-Resistant Prostate Cancer (CRPC)

Researchers have found that a deeper look at proteins and cells may help explain why prostate cancer tumors often become resistant to hormone therapy.

In this episode of the “CURE® Talks Cancer” podcast, Leanne Burnham, Ph.D., discusses the research she’s working on to address health disparities in Black men with prostate cancer after being inspired by her father’s diagnosis, and shares her own cancer survival story.

I see a psychologist who is helping me to understand my feelings and to learn mindfulness meditation techniques.

On this week’s episode of the CURE Talks Cancer podcast, we talk with Grammy-winning songwriter and vocal producer Kuk Harrell about what it’s like to be “on the other side” of his prostate cancer diagnosis, and how he’s using his platform to shine a light on the disease.

The Food and Drug Administration approved six new cancer therapies in November 2023.

The Food and Drug Administration approved Xtandi for non-metastatic castration-sensitive prostate cancer at high risk for biochemical recurrence.